We need to continue investing in research for early stage, localized prostate cancer, develop treatments that balance efficacy with quality-of-life considerations, ensure diverse representation in clinical trials, and listen to patients and incorporate their perspectives into treatment development and decision-making.
AI-powered solutions for opportunistic lung cancer detection using routine chest X-rays offer hope for improved early diagnosis and survival rates.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The current imaging interpretation model undoubtedly has reached its breaking point due to increasing volumes and fewer radiologists. The time is now to solve this systemic imaging interpretation issue.
New York-based startup Ezra recently received FDA clearance for an AI tool it plans to use to launch “the world's first 30-minute full body MRI scan.” The tool, named Ezra Flash, enhances the quality of MR images so that radiologists can detect cancer earlier.
Fewer people are dying from cancer due to advances in research, screening and treatment, according to a new report. In order for the death rate to fall further, U.S. oncologists must prioritize personalized treatment and addressing social determinants of health, an expert argued.
Grail, a company focused on early cancer detection, introduced its test that screens for more than 50 kinds of cancer last year. At AWS' Thursday conference for healthcare and life sciences innovation, the company's chief security officer explained how the company is evaluating the test in clinical trials and preparing to file for its FDA approval.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The Dublin-based pathology software and services provider will use the funds to support global growth and launch an on-demand, online pathology service in the U.S.
The companies tout the deal as expanding Exact's commercial footprint to 90 countries and creating a leader in the cancer diagnostic space with projected 2020 revenues of $1.6 billion.